Explore › Finding
Finding null
There was no significant difference in complete remission rate, CRS, NTX/ICANS, or infections between patients who received high-intensity versus low-intensity bridging chemotherapy, despite high-intensity bridging achieving more tumor debulking (41% vs 0%, p=0.020).
ComparatorLow-intensity bridging chemotherapy (myelosuppression <=7 days) prior to CAR T cell infusion
Effect summarynull

Connected entities

Interventions
High-intensity bridging chemotherapy
Conditions
Precursor B-cell acute lymphoblastic leukemia in remission
Outcomes
Clinical Outcomes in Routine Evaluation Learning Disabilities

Source

PMC9361393
Impact of Bridging Chemotherapy on Clinical Outcomes of CD19-Specific CAR T Cell Therapy in Children/Young Adults with Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia
Read on PMC → · View in graph →